The objective of this research is to examine how liposome encapsulation affects the accumulation kinetics of a clinical iodinated computed tomography (CT) contrast medium (CM) in the kidneys. Preliminary findings suggest that encapsulating the CM in liposomes significantly reduces the mean accumulation concentration in the kidneys, particularly in the time window between 30 and 300 min, where reductions of 50–76% were observed. Furthermore, the study found that liposome encapsulation led to a 64–86% reduction in the distribution of harmful CM dosages (>9 mg/ml) within the kidneys, especially during the 10–90 min period. This change in distribution resulted in the contrast medium being more concentrated in the renal pelvis, rather than the renal medulla, an area typically unaffected by nephropathy. These results suggest that liposome encapsulation may offer a strategy for reducing the adverse impact of CT contrast agents on kidney tissues, potentially improving the safety profile of iodinated CM in clinical imaging procedures. The findings provide valuable insights into how altering the pharmacokinetics of contrast media through liposomal formulations may enhance the clinical application of CT imaging while minimizing kidney-related side effects.